Duke Street Bio Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.dukesb.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Phase 1
Recruiting
- Conditions
- Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-10-31
- Lead Sponsor
- Duke Street Bio Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT06458712
- Locations
- 🇺🇸
Yale Cancer Center - Yale New Haven Hospital, New Haven, Connecticut, United States
🇫🇷Institut Bergonie, Bordeaux, France
🇪🇸Universitary Hospital Virgen del Rocio, Seville, Spain
News
No news found